Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.
Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA.
Park ES, et al. Among authors: mills gb.
Mol Cancer Ther. 2010 Feb;9(2):257-67. doi: 10.1158/1535-7163.MCT-09-0743. Epub 2010 Feb 2.
Mol Cancer Ther. 2010.
PMID: 20124458
Free PMC article.